+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects



Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects



Journal of Clinical Endocrinology and Metabolism 70(2): 324-327



It is well known that GH responses to GH-releasing hormone (GHRH) show marked interindividual variations in normal subjects, which have been attributed to a variable somatostatinergic tone. Recently, it has been shown that enhancement of cholinergic tone with the acetylcholinesterase inhibitor pyridostigmine (PD), which presumably acts by inhibiting somatostatin release, stimulates basal GH secretion and GH responses to a maximal dose of GHRH. In this study we have investigated the effects of PD on the dose-response relationships of GHRH-induced GH secretion in normal subjects. Our data showed that PD (120 mg, orally, at-60 min) induced a clear-cut increase in basal GH levels, significantly different from that after saline treatment, at 15, 30, 45, 60, 90, and 120 min. Moreover, PD administration markedly potentiated GH responses to GHRH at doses of 500, 100, 25, 10, and 3 micrograms/subject, as assessed by either area under the curve or maximal peak GH levels. In fact, GH responses to pyridostigmine plus 3 micrograms GHRH were similar to those to the administration of 500 and 100 micrograms GHRH alone. Our findings of marked increases in GH response to GHRH after pyridostigmine administration show that with enhancement of cholinergic tone, the dose of GHRH needed to induce a similar increase in GH is reduced 30 times.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039918795

Download citation: RISBibTeXText

PMID: 2105328

DOI: 10.1210/jcem-70-2-324


Related references

Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion. Acta Endocrinologica 126(2): 113-116, 1992

Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome. Clinical Endocrinology 33(2): 291-295, 1990

Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature. Journal of Clinical Endocrinology and Metabolism 65(3): 452-456, 1987

Effect of cholinergic tone on growth hormone-releasing hormone-induced secretion of growth hormone in normal aging. Aging 4(3): 231-237, 1992

Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects. Journal of Clinical Endocrinology and Metabolism 70(5): 1361-1370, 1990

Comparative effect of galanin and pyridostigmine on the growth hormone response to growth hormone-releasing hormone in normal aged subjects. Hormone Research 37(4-5): 165-170, 1992

Effect of the enhancement of the cholinergic tone by pyridostigmine on the exercise-induced growth hormone release in man. Journal of Endocrinological Investigation 16(6): 421-424, 1993

Effect of enhancement of cholinergic tone on the growth hormone response to acute hyperglycaemia or thyrotropin-releasing hormone in dogs. Journal of Neuroendocrinology 4(1): 63-66, 1992

Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man. Journal of Clinical Endocrinology and Metabolism 71(3): 580-584, 1990

Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?. Neuroendocrinology 49(5): 551-554, 1989

Activation of Cholinergic Neurotransmission by Pyridostigmine Reverses the Inhibitory Effect of Hyperglycemia on Growth Hormone (Gh) Releasing Hormone-Induced Gh Secretion in Man: Does Acute Hyperglycemia Act through Hypothalamic Release of Somatostatin?. Neuroendocrinology 49(5): 551-554, 1989

Effect of Combined Administration of Growth Hormone (GH)-Releasing Hormone, GH-Releasing Peptide-6, and Pyridostigmine in Normal and Obese Subjects. Metabolism Clinical and Experimental 44(6): 745-748, 1995

Influence of pyridostigmine on growth hormone (GH) response to GH-releasing hormone pre- and postprandially in normal and obese subjects. Journal of Clinical Endocrinology and Metabolism 74(6): 1253-1257, 1992

The role of cholinergic tone in modulating the growth hormone response to growth hormone-releasing hormone in normal man. Metabolism: Clinical and Experimental 40(5): 519-523, 1991

Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release. Clinical Endocrinology. 46(2): 202, 1997